🥇 Alexis Moscoso Rial (@AlexisMoscoso9) es el ganador en los II Premios de Investigación en Salud Transfronterizos Galicia - Norte de Portugal, en la modalidad de trayectorias emergentes de investigación en salud.
Grateful for this recognition of my research trajectory 🙏. Excited to keep driving impactful projects in neuroimaging & biomarkers for neurodegenerative diseases from Galicia, in close collaboration with the Galician public healthcare system.
🥇 Enhorabuena a nuestro investigador del grupo Imagen Molecular #IDIS@AlexisMoscoso9 por el primer premio en categoría Trayectorias Emergentes de Investigación en Salud de los Premios de Investigación en Salud Transfronterizos #TransfireSaúde@ACIS_sergas@SanidadeXunta
Editorial: Plasma p-tau217 is a promising yet complementary #Alzheimer biomarker, aiding diagnosis and trial efficiency but not fully replacing CSF and PET, especially in those without cognitive impairment.
https://t.co/AvJ4dqlZnA
Do p-tau217 levels rise without amyloid or tau aggregates? 🐻
In our Acta Neuropathologica paper, we show that 🩸 p-tau217 increases ~300% during bear hibernation, while hibernating hamsters also show ⬆️ p-tau but no changes in MTBR tau.
https://t.co/8QgRj9hfR9
Largest-ever tau-PET studies confirm ties between tangles and cognitive decline. ApoE4 carriers and women get tangles earliest. @_michael_scholl@AlexisMoscoso9@amsterdamumc https://t.co/gdoBh1zDX2
Our most important paper, out now! A massive international collaboration, led by @AlexisMoscoso9, featuring over 6500 visually assessed tau PET scans covering the #Alzheimers spectrum!
Thank you very much to the numerous contributors and collaborators who made this gem possible.
Tau PET brain scans can help to identify the risk of clinical progression in both the preclinical and symptomatic stages of Alzheimer’s disease, a Swedish-led study finds. https://t.co/vV6GqTUFlZ #Radiology#petscan#NucMed#MolRad#MolecularImaging
This study also marks the culmination of an intense period in my career. From now on, my aim will be to contribute in a different manner, in contact with drug development and the use of biomarkers in trials.
Stay tuned—more to come!
After more than 3 years of work, visualizing over 6,500 tau PET scans, and countless manuscript revisions, I still have to blink twice to believe it: our paper “Frequency and Clinical Outcomes Associated With Tau PET Positivity” is now published in JAMA.
https://t.co/8iGcly62Qe